

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> <b>C12N 15/00, 15/11, A61K 48/00</b> <b>A01K 67/027, C12N 5/10, 15/12</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 93/10227</b> <b>(43) International Publication Date:</b> 27 May 1993 (27.05.93)
<b>(21) International Application Number:</b> PCT/EP92/02631 <b>(22) International Filing Date:</b> 16 November 1992 (16.11.92) <b>(30) Priority data:</b> 792,509 14 November 1991 (14.11.91) US <b>(60) Parent Application or Grant</b> <b>(63) Related by Continuation</b> US 792,509 (CIP) <b>(71)(72) Applicants and Inventors:</b> WEISSMANN, Charles [CH/CH]; Eschenhastrasse 39, CH-8053 Zürich (CH). BUELER, Harsruedi [CH/CH]; Riedweg 7, CH-8600 Dubendorf (CH). AGUET, Michel [CH/CH]; Hadlaubstrasse 49, CH-8006 Zürich (CH). FISCHER, Marek [CH/CH]; Rothstrasse 19, CH-8057 Zürich (CH).	<b>(74) Agent:</b> VOSSIUS & PARTNER; Siebertstrasse 4, P.O. Box 86-07 67, D-8000 Munich 86 (DE).  <b>(81) Designated States:</b> JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	

**(54) Title:** TRANSGENIC ANIMALS LACKING PRION PROTEINS**(57) Abstract**

This invention relates to transgenic mammals and birds that are not susceptible to spongiform encephalopathies (i.e., scrapie-like or prion diseases), due to absence of endogenous functional prion protein ("PrP"). More particularly, this invention relates to DNA targeting molecules that specifically disrupt PrP genes by homologous recombination in transfected animal cells, to cultured cells transformed with such DNA targeting molecules, and to animals derived from those transformed cells and the transgenic progeny of such animals.



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

- 1 -

TRANSGENIC ANIMALS LACKING PRION PROTEINSTECHNICAL FIELD OF THE INVENTION

This invention relates to transgenic mammals and birds ("animals") that are not susceptible to spongiform encephalopathies (i.e., scrapie-like or prion diseases), due to absence of endogenous prion protein ("PrP"). More particularly, this invention relates to targeting molecules that are capable of disrupting PrP genes, PrP genes that are disrupted by such targeting molecules and thus incapable of expressing functional prion protein, to cultured cells transformed to have such disrupted genes, to mammals and birds derived from those transformed cells and to the transgenic progeny of such animals.

15                   BACKGROUND OF THE INVENTION

Prions are infectious pathogens that cause spongiform encephalopathies in humans and animals. Prions are distinct from bacteria, viruses and viroids. The predominant hypothesis at present is that no nucleic acid component is necessary for infectivity of prion protein.

Kuru, Creutzfeldt-Jakob disease ("CJD") and Gerstmann-Sträussler-Scheinker syndrome ("GSS") are fatal human neurodegenerative diseases caused by prions. Scrapie of sheep and goats is the most well-

- 2 -

studied prion disease. Bovine spongiform encephalopathy ("BSE" or "mad cow disease") is a prion disease that currently threatens the beef industry in Great Britain. Transmissible mink encephalopathy and chronic wasting disease of deer and elk are also thought to be prion diseases. The pathological characteristics of prion diseases include neuronal vacuolation, astrocytic gliosis, and amyloid plaques with filaments composed of prion protein.

10 A major step in the study of prions and the diseases that they cause was the discovery and purification of a protein designated prion protein ("PrP") (Bolton et al., Science 218, pp. 1309-11 (1982); Prusiner et al., Biochemistry 21, pp. 6942-50 (1982); McKinley et al., Cell 35, pp. 57-62 (1983)).  
15 Complete prion protein-encoding genes have since been cloned, sequenced and expressed in transgenic animals. PrP<sup>C</sup> is encoded by a single-copy host gene (Basler et al., Cell 46, pp. 417-28 (1986)) and is normally  
20 found at the outer surface of neurons. A leading hypothesis is that prion diseases result from conversion of PrP<sup>C</sup> into a modified form called PrP<sup>Sc</sup>.

The actual biological or physiological function of PrP<sup>C</sup> is not known. Suggestions that it is  
25 identical with acetylcholine receptor inducing activity ("ARIA") remain to be confirmed (Harris et al., Proc. Natl. Acad. Sci. USA 88, pp. 7664-68 (1991)). The PrP gene, however, is found in all mammals so far examined, i.e., hamster (Basler et al., Cell 46, pp. 417-28 (1986)), mouse (Locht et al., Proc. Natl. Acad. Sci. USA 83, pp. 6372-76 (1986)), human (Kretzschmar et al., DNA 5, 315-24 (1986); Puckett et al., Am. J. Hum. Genet. 49, 320-29 (1991)), rat (Westaway and Prusiner, Nucl. Acids Res. 14, 2035-44 (1986)), cattle (Goldmann  
35 et al., J. Gen. Virol. 72 pp. 201-04 (1991)), sheep

- 3 -

(Goldmann et al., Proc. Natl. Acad. Sci. USA 87, pp. 2476-80 (1990)), and goat (Westaway and Prusiner, supra). The PrP gene is also found in chickens (Harris et al., Proc. Natl. Acad. Sci. USA 88, pp. 7664-68 (1991)). Furthermore, because PrP<sup>C</sup> is expressed in neurons of the brain (Kretzschmar et al., Am. J. Pathol. 122, pp. 1-5 (1986)) as well as in lymphocytes (Cashman et al., Cell 61, pp. 185-92 (1990)) and shows a high turnover rate (Caughey et al., J. Virol 63, pp. 15-81 (1989); Borchelt et al., J. Cell. Biol. 110, pp. 743-52 (1990)), it would seem to be of considerable physiological importance.

The central role of PrP<sup>C</sup> in scrapie-like diseases is indicated by several lines of evidence.

15 The infectious agent copurifies with PrP<sup>Sc</sup> by different procedures (Prusiner, Science 216, pp. 136-44 (1982); Diringier et al., Nature 306, pp. 476-78 (1983); McKinley et al., Cell 35, pp. 57-62 (1983); Hope et al., EMBO J. 5, pp. 2591-97 (1986)), including

20 affinity purification on an anti-PrP antibody column (Gabizon et al., Proc. Natl. Acad. Sci. USA 85, pp. 6617-21 (1988)), SDS-polyacrylamide gel electrophoresis (Brown et al., Proc. Natl. Acad. Sci. USA 87, pp. 7240-44 (1990)) and HPLC (Safar et al.,

25 Proc. Natl. Acad. Sci. USA 87, pp. 6373-77 (1990)). Further, the susceptibility of a host to scrapie is determined, at least in part, by the nature of its Prn-p alleles (Dickinson et al., J. Comp. Pathol. 78, pp. 293-99 (1968); Dickinson and Meikle, Mol. Gen.

30 Genet. 112, pp. 73-79 (1971); Carlson et al., Cell 46, pp. 503-11 (1986); Hunter et al., J. Gen. Virol. 68, pp. 2711-16 (1987); Carlson et al., Proc. Natl. Acad. Sci. USA 86, pp. 7475-79 (1989); Race et al., J. Gen. Virol. 71, pp. 493-97 (1990); Westaway et al., Neuron

35 7, pp. 59-68 (1991)). Finally, certain mutations in

- 4 -

the PrP gene, such as a proline to leucine change in position 102, are tightly linked to morbidity in some familial forms of spongiform encephalopathies (Hsiao et al., Nature 338, pp. 342-45 (1989); Hsiao and Prusiner, Neurology 40, pp. 1820-27 (1990)). Furthermore, mice carrying a PrP transgene with the analogous amino acid change succumb to a spontaneous scrapie-like disease (Hsiao et al., Science 250, pp. 1587-90 (1990)). However, to date there has been no way to prevent the disease.

#### SUMMARY OF THE INVENTION

This invention solves the above problem. It relates to mammals and birds lacking functional PrP genes, and thus devoid of prion proteins. Those transgenic animals not only survive and develop normally, but they are not susceptible to prion diseases. More particularly, this invention relates to PrP genes that are disrupted and thus incapable of expressing prion protein, to PrP antisense genes, to cultured cells transformed with such disrupted genes or antisense genes, and to mammals and birds derived from those transformed cells and to transgenic progeny of such animals. This invention also relates to therapeutic administration of antisense oligonucleotides to non-transgenic animals and humans who have an incipient spongiform encephalopathy.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 depicts construction of plasmid pBluescriptPrP-2 from the Westaway cosmid and plasmid pBluescript.

Figure 2 depicts construction of plasmid pRVPrPneoPA2 from plasmids pBluescriptPrP-2 and pMC1neo.

- 5 -

Figure 3 depicts construction of "fragment 1" and "fragment 2" used to construct the targeting plasmid pRVPrP3.

Figure 4 depicts the synthesis of  
5 "Fragment 3" by the polymerase chain reaction ("PCR") method, using linearized pBluescript-PrP2 as the template. "Fragment 3" is used to construct the targeting plasmid pRVPrP3.

Figure 5 depicts construction of the  
10 targeting plasmid from fragments 1-3, and excision of the targeting fragment from the targeting plasmid.

#### DETAILED DESCRIPTION OF THE INVENTION

In the description of the present invention, the following terms are employed:

15 Critical site -- Site (or sites) within a PrP gene that is required for expression of functional prion protein.

Disrupting sequence -- Nucleotide sequence in a targeting molecule that disrupts a target gene upon  
20 site-specific integration of the targeting molecule so as to prevent expression of functional PrP protein.

ES cells -- Embryonic stem cells.

Expression control sequence -- Sequence of nucleotides that enables and regulates transcription of  
25 a nucleotide sequence when operatively linked to that sequence.

Homologous recombination -- Rearrangement of DNA segments at a sequence-specific site (or sites) within or between DNA molecules through base-pairing  
30 mechanisms.

Homologous region -- Sequence within the target gene locus chosen for duplication in the targeting molecule, having sufficient length and homology to provide for site-specific integration of

- 6 -

the targeting molecule into the target gene locus by homologous recombination.

PCR -- Polymerase chain reaction.

PrP -- Prion protein.

5        Prn-p -- Gene encoding prion protein.

Target gene locus -- Chromosomal site of target gene, including the PrP coding sequence, PrP expression control sequences, PrP 3' untranslated sequences, and 5' and 3' PrP gene-neighboring regions  
10 on the chromosome.

Targeting fragment -- Targeting molecule consisting of fragment from targeting plasmid.

Targeting molecule -- DNA molecule, linear or circular, capable of specifically disrupting a PrP  
15 target gene in a transfected cell by homologous recombination so as to prevent expression of functional PrP protein.

Targeting plasmid -- Intermediate in construction of targeting fragment.

20        The first step in producing the transgenic animals of this invention is to prepare a DNA sequence ("targeting molecule") that is capable of specifically disrupting a PrP gene in animal cells carrying that gene and rendering that gene non-functional. The  
25 targeting molecule is then used to transfect animal cells and to disrupt the functional PrP genes in those cells. The transgenic animal cells may then be used to produce the transgenic mammals and birds of this invention.

30        DNA targeting molecules that are capable, in accordance with this invention, of disrupting a functional PrP gene resident in cells may be produced using information and processes well known in the art.

- 7 -

Any DNA targeting molecule of the present invention has two essential functions. Those essential functions are to integrate at a native resident PrP gene ("target gene locus") and to disrupt PrP gene expression associated with that locus so that no functional PrP expression is possible. Those two essential functions depend on two basic structural features of the targeting molecule.

The first basic structural feature of the targeting molecule is a pair of regions that are homologous to chosen regions of the target gene locus. That homology (in terms of both sequence identity and length) causes the targeting molecule to integrate by base pairing mechanisms ("homologous recombination") at the site chosen in the target gene locus in transfected cells.

Homologous recombination is the rearrangement of DNA segments at a sequence-specific site (or sites) within or between DNA molecules through base-pairing mechanisms. The present invention relates to a particular form of homologous recombination sometimes called "gene targeting". In gene targeting, an exogenous "targeting molecule" (or "targeting fragment") is introduced into cells. The targeting molecule has one or more regions of homology with a chromosomal gene to be modified or replaced ("target gene"). The regions of homology between the target gene and the targeting molecule result in site-specific integration of the exogenous sequence. Of course, the exogenous sequence may be designed to correct an existing defect in the resident gene or to disable ("disrupt") a functional resident gene. The present invention relates to disrupting PrP genes. Gene targeting, which affects the structure of a specific gene already in a cell, is to be distinguished from

- 8 -

other forms of stable transformation wherein integration of foreign DNA for expression is not site-specific, and thus does not predictably affect the structure of any particular gene already in the cell.

5           The second basic structural feature of the targeting molecule of this invention is a disrupting sequence between the homologous regions. The disrupting sequence prevents expression of functional prion protein from the PrP target gene following the  
10 replacement of a portion of that target gene by the integrated targeting molecule.

One of skill in the art will recognize that numerous embodiments of the PrP gene targeting molecule of the present invention may be constructed to fulfill  
15 the structural and functional requirements specified above. Example 1 (below) describes the actual construction of a PrP gene targeting molecule used to produce the transgenic mice of the present invention. The following discussion sets forth considerations and  
20 parameters that can be used to design other PrP gene targeting molecules that may be used to produce transgenic mice, hamsters, rabbits, sheep, pigs, cattle, chickens and other mammals and birds without departing from the scope of the present invention.

25           Parameters of the targeting molecule that may be varied in the practice of the present invention include the lengths of the homologous regions, what regions of the target gene locus are to be duplicated as the homologous regions of the targeting molecule,  
30 the length of the disrupting sequence, the identity of the disrupting sequence, and what sequence of the target gene is to be replaced by the targeting molecule.

The length of the homologous regions that  
35 flank the disrupting sequence of the targeting

- 9 -

molecules of this invention can vary considerably without significant effect on practice of the invention. The homologous flanking regions must be of sufficient length for effective heteroduplex formation

5 between one strand of the targeting molecule and one strand of a transfected cell's chromosome, at the PrP target gene locus. Increasing the length of the homologous regions promotes heteroduplex formation and thus targeting efficiency. However, it will be

10 appreciated that the incremental targeting efficiency accruing per additional homologous base pair eventually diminishes and is offset by practical difficulties in targeting molecule construction, as homologous regions exceed several thousand base pairs. A preferred range

15 for the length of each homologous region is 50 to 5,000 base pairs, and about 500 base pairs is most preferred. It should be further noted that the precise length of the homologous regions in the DNA targeting molecule may depend in practice on the location of restriction

20 sites in and around the PrP gene. For a discussion of the length of homology required for gene targeting in embryonic stem cells, see Hasty et al. (Mol. Cell Biol. 11, 5586-91 (1991)).

There is considerable latitude in choice of

25 which regions of the target gene locus are duplicated as the homologous regions in the targeting molecule. The basic constraints are that the PrP target gene sequence to be replaced by the disrupting region must lie between the regions of the target gene locus

30 duplicated as the homologous regions in the targeting molecule, and that replacement of the target gene sequence must render the PrP gene non-functional. It should be noted that the target gene locus nucleotide

- 10 -

sequences chosen for homology in the targeting molecule remain unchanged after integration of the targeting molecule. Those sequences of the target gene locus are merely replaced by the duplicate (homologous) sequences in the targeting molecule. Identity between the chosen regions of the target gene locus and the homologous regions in the targeting molecule is the means by which the targeting molecule delivers the disrupting sequence precisely into the PrP target gene. The chosen regions of homology may lie within the PrP coding sequence, but it is not necessary that they do so. For example, in an embodiment of the present invention, one homologous region could be located 5' from the PrP gene, and the other homologous region could be located 3' from the PrP gene. Preferably, the PrP initiation codon and 5' terminal region of the PrP coding sequence will lie between the chosen homologous regions and thus be replaced by the interrupting sequence, so that no portion of the prion protein can be expressed. Even more preferred, when the interrupting sequence contains a selectable marker (or any other gene), is that there is a termination codon downstream of the minimum required marker coding sequence, and in-frame with the marker coding sequence, to prevent translational read-through that might yield a PrP fusion protein with PrP activity. As a practical matter, other than the requirement that some critical site of the PrP gene lie between the homologous regions (so that it will be disrupted), the primary constraints on choice of homologous regions is the availability of the cloned sequences and the existence of restriction sites therein. Preferably, the regions chosen to be homologous regions will not include sequences longer

- 11 -

than about 20 nucleotides that are known to occur elsewhere in the genome being modified. Extensive homology between the targeting molecule and other (non-target) sites in the genome might diminish targeting efficiency by diverting targeting molecules into non-productive heteroduplexes at non-target sites.

The length of the disrupting sequence separating the homologous regions in the targeting molecule can also vary considerably without significant effect on the practice of the present invention. The minimum length of the disrupting sequence is one base pair. Insertion of a single base pair in the PrP coding sequence would constitute a frame shift mutation and thus could prevent expression of a functional prion protein. Alternatively, a single base pair substitution could result in an amino acid substitution at a critical site in the prion protein and the expression of only non-functional prion protein. It should be recognized, however, that a single base pair alteration is susceptible to reversion to the wild type sequence through spontaneous mutation. For that reason, disrupting sequences longer than one base pair are preferred. At the other extreme, excessive length in the disrupting sequence would be unlikely to confer any advantage over a disrupting sequence of moderate length, and might diminish efficiency of transfection or targeting. Excessive length in this context is many times longer than the distance between the chosen homologous regions on the target gene. A preferred length for the disrupting sequence is from 2 to 2,000 base pairs. A more preferred length for the disrupting sequence is a length approximately equivalent to the distance between the regions of the target gene locus

- 12 -

that match the homologous regions in the targeting molecule.

There is wide latitude in the choice of the of the disrupting sequence, since the disrupting  
5 function is not sequence-specific. It is necessary, however, that the nucleotide sequence of the disrupting region not express a functional prion protein and not express a protein or polypeptide toxic to the transformed cell. It is also preferred that the  
10 disrupting sequence not be extensively homologous to sites in the genome of the transfected cell. Such homology would be likely to diminish the efficiency of the targeting molecule, and might severely impair its function.

15 For some embodiments of the present invention it is preferred that the disrupting sequence have a dual function, i.e., be both a selectable marker and a disrupting sequence. In those embodiments, the length and identity of the disrupting sequence will be  
20 determined largely by the selectable marker coding sequence and associated expression control sequences. The selectable marker gene provides for positive selection of transfected cells that have taken up and integrated the targeting molecule. The need for a  
25 selectable marker will depend on the methods chosen for transfection of cells and transgenic animal production. The choice of those methods, in turn, will depend on the species of animal on which this invention is being practiced. For example, a preferred method for  
30 production of transgenic birds (described below) does not comprise a selectable marker. In another example (Examples 1 and 2 below), a preferred method for production of transgenic mice involves murine ES cells,

- 13 -

and a preferred method of transfecting ES cells is electroporation, with which a selectable marker is preferred. The preferred selectable marker is the antibiotic resistance gene, neomycin phosphotransferase 5 ("neo"). A neo gene with mammalian expression control sequences is commercially available (Stratagene Cloning Systems, La Jolla, CA). Although neo is preferred for mammalian cell selection, other marker genes, such as thymidine kinase, dihydrofolate reductase, hygromycin B 10 phosphotransferase, xanthine-guanine phosphoribosyl transferase, adenosine deaminase, asparagine synthetase and CAD (carbamyl phosphate synthetase/aspartate transcarbamylase/dihydroorotase) may be used with appropriate culture media.

15 In plasmid pRVPrP3, the targeting plasmid of the present invention described in Example 1 below and Figures 1-5, 72% (codons 4 to 187) of the PrP coding sequence was replaced with a fragment containing a neo gene under the control of the HSV TK promoter (Thomas and Capecchi, Cell 51, pp. 503-12 (1987)). 20

In this discussion, the targeting molecule is described as a linear DNA molecule. However, it should be recognized that a targeting molecule of the present invention could also be embodied as a circular DNA 25 molecule. A circular targeting molecule could comprise a pair of homologous regions separated by a disrupting region, as described for a linear targeting molecule. Alternatively, a circular targeting molecule could comprise a single homologous region. Upon integration 30 at the target gene locus, the circular molecule would become linearized, with a portion of the homologous region at each end. Thus, the single homologous region effectively becomes two homologous regions, as

- 14 -

described in the discussion of linear targeting molecules (see Watson et al., Molecular Biology of the Gene (4th Ed.), Benjamin/Cummings, Menlo Park, CA, p. 606). One differing aspect of a circular targeting  
5 molecule with a single homologous region is that it inserts the disrupting sequence into the target gene and disrupts it without replacing any of the target gene. A second differing aspect is that the single homologous region must be within the target gene and  
10 located 5' to at least one critical site in the PrP coding sequence.

The foregoing discussion focuses on PrP gene disruption by homologous recombination, for production of transgenic animals devoid of prion protein -- the  
15 preferred embodiment. However, in another embodiment the present invention also provides heterozygous animals having one gene encoding prion protein. Such animals are at least partially protected against scrapie. They produce prion protein, but at a lowered  
20 level, due to a gene dosage effect. (Wild type animals have two prion genes.) And this lowered prion protein level confers significant resistance against spongiform encephalopathy.

Lowering of prion protein levels, without PrP  
25 gene disruption, is thus an alternative means, in accordance with this invention, of producing resistance to spongiform encephalopathy. One of skill in the art can, for example, advantageously reduce prion protein levels by application of well known antisense  
30 techniques. Antisense techniques, for example, may be applied in either of two different approaches. The first antisense approach is production of transgenic animals whose cells transcribe prion antisense

- 15 -

sequences. The second antisense approach is therapeutic administration of antisense oligonucleotides to non-transgenic animals and humans who have an incipient spongiform encephalopathy.

5               Ribozymes are RNA molecules with endoribonuclease activity. Ribozyme sequences may be combined with antisense sequences to specifically inhibit production of a particular protein. In an additional embodiment of this invention, one of  
10 ordinary skill in the art can advantageously reduce prion protein levels by linking ribozyme sequences to prion antisense sequences, thereby targeting the endoribonuclease activity specifically to the prion mRNA, to inhibit biosynthesis of prion protein. Such a  
15 prion antisense-ribozyme RNA molecule may be provided indirectly by transcription of a recombinant DNA construct in the cells of transgenic animals. Alternatively, such a prion antisense-ribozyme RNA molecule may be provided directly by therapeutic  
20 administration of the RNA molecule to non-transgenic animals or humans. For a general discussion of ribozyme technology, see, inter alia: Cech, "Ribozymes and Their Medical Implications", J. American Medical Association, vol. 260, pp. 3030-34 (1988); Haseloff and  
25 Gerlach, "Simple RNA Enzymes with New and Highly Specific Endoribonuclease Activities", Nature, vol. 334, pp. 585-91 (1988).

It should be recognized from the foregoing discussion that practice of the present invention  
30 requires a DNA clone comprising at least a portion of the PrP target gene or DNA clones comprising sequences between which at least a portion of the PrP target gene lies. Such DNA clones necessary for practice of the

- 16 -

present invention may be obtained by a variety of means. Mouse (Locht et al. Proc. Natl. Acad. Sci. USA, 83, pp. 6372-76 (1986)), hamster (Basler et al., Cell, 46, pp. 417-28 (1986)), sheep (Goldmann et al., Proc. Natl. Acad. Sci. USA 87, pp. 2476-80 (1990)), cow (Goldmann et al., J. Gen. Virol. 72, pp. 201-04 (1991)) and human (Kretzschmar et al., DNA 5, pp. 315-24 (1986)) PrP genes have been cloned and sequenced. DNA clones suitable for practice of the present invention on those species may be obtained by following the PrP gene cloning methods set forth in the publications cited above, by use of the sequences published therein for chemical synthesis of PrP genes or portions thereof, or by use of the published sequences for chemical synthesis of oligonucleotide probes which may be used in well-known procedures to isolate PrP gene sequences from a cDNA library or a genomic library. The published nucleotide sequence of a PrP gene from one species, can be used to obtain a PrP gene from another species, without undue experimentation, because the nucleotide sequences of all known PrP coding regions are highly conserved (80%-90% identical). In addition, even the 3' untranslated regions are conserved in hamsters, sheep and humans. The use of a PrP gene sequence from one sequence to isolate a PrP gene from a different species has been demonstrated by Goldmann et al. (supra), who isolated a sheep PrP gene by screening a sheep genomic library with a hamster PrP cDNA.

The preferred method of obtaining a cloned PrP gene sequence is:

(a) using published PrP gene sequence data to synthesize oligonucleotide primers (representing the

- 17 -

ends of the desired DNA fragment), using known techniques, and

(b) using the primers prepared in (a) in known PCR procedures, wherein DNA from the animal  
5 species of interest serves as the template.

DNA targeting molecules constructed to disrupt PrP genes according to the present invention may be used to transfect animal cells using well known techniques. Such transfection results in the DNA  
10 sequences of this invention disrupting the functional PrP genes in those animal cells. The cell type chosen for transfection with the PrP targeting molecule must be pluripotent. The defining characteristic of pluripotent cells is developmental plasticity, which is  
15 necessary for production of a transgenic animal. Pluripotent cells are exemplified by oocytes, sperm and embryonic cells. Oocytes and embryonic cells are preferred in the practice of the present invention. Animal species is a major factor in the choice of  
20 pluripotent cell type to be used in practicing the present invention. For example, ES cell culture methods are not fully developed for all species.

Single-cell embryos (also called zygotes) are preferred for transfection and production of transgenic  
25 mammals such as pigs, sheep and cattle. Single cell embryos are either obtained surgically or produced by in vitro fertilization. Embryonic stem cells maintained in culture are preferred for the production of transgenic small mammals such as mice and hamsters.  
30 Embryonic cells of a newly laid egg are preferred for production of transgenic birds such as chickens.

The method of Krimpenfort et al.

(Bio/Technology 9, pp. 844-47 (1991)) is preferred for

- 18 -

production of transgenic cattle and other large mammals in accord with the present invention. In that method, immature oocytes are collected by aspiration of follicles on ovaries from slaughtered animals. The oocytes are fertilized in vitro by standard techniques. The DNA targeting molecule is placed in the pronucleus of the single-cell embryo by microinjection at an appropriate time interval after oocyte fertilization (between 16 and 23 hours for cattle). Differential interference contrast microscopy is preferred for microinjection of bovine zygotes, due to their opacity. The embryos are cultured for an appropriate period following microinjection (nine days for cattle), and they are then evaluated for development and normal appearance. An animal that started estrous on the same day that the oocytes were fertilized is used as a recipient of one or two cultured embryos that have developed to the compact morula or early blastula stage.

20 In an alternative microinjection approach for producing transgenic mammals, including sheep and cattle, early embryos are obtained surgically from oviducts of superovulated, artificially inseminated mammals, subjected to microinjection of the PrP targeting molecule, and transferred back to the donor female or another physiologically receptive female for gestation (Ebert et al., Bio/Technology 9, pp. 835-38 (1991)). The use of embryos retrieved after in vivo fertilization may yield a somewhat higher number of transgenic animals per embryo, but the method is more labor-intensive than the method of Krimpenfort et al., described above. For a discussion of surgical

- 19 -

techniques used to obtain single-cell embryos from sheep, see PCT patent publication WO 90/08832.

ES cell culture can be used to produce transgenic animals of the present invention without  
5 microinjection. For a discussion of the culturing of ES cells and their use in the production of transgenic animals, see PCT patent publication WO 90/0154. ES cells are preferred for the production of small transgenic mammals with short generation intervals and  
10 large litter size. Generation interval and litter size are factors to be considered, because the ES cell method yields chimeric animals. Advantages of the ES cell method are that ES cells can be maintained in culture in large numbers, and they can be efficiently  
15 transformed by standard electroporation techniques. Following electroporation, transformed ES cell clones are isolated by use of positive selection for a marker gene within the DNA targeting molecule. Prior to use in production of transgenic animals, the selected ES  
20 cell clones are analyzed for the presence of disrupted PrP genes. ES cells from a clone found to have a disrupted PrP gene are injected into cultured blastocysts. Following implantation of the blastocysts in utero, the ES cells become part of the embryo and  
25 give rise to chimeric animals. In the chimeric animals, only the body tissues derived from the transgenic ES cells are transgenic. However, transgenic germ cells transmit the transgene to offspring according to normal hereditary principles.  
30 Fusion with bacterial protoplasts, calcium-phosphate-mediated transfection, and DEAE-Dextran-mediated transfection have been used to introduce foreign DNA into mammalian cells. Although those

- 20 -

methods may be used in the present invention, they are not preferred.

#### Production of Transgenic Birds

Transgenic chickens have been produced  
5 (Salter et al., Virology, 157, pp. 236-40 (1987);  
Bosselman et al., Science 243, 533-35 (1989); European  
Patent Publication 0424044A1). However, avian anatomy  
and physiology make manipulation and culturing of the  
early embryo impractical. Therefore, techniques such  
10 as direct microinjection of the pronucleus of  
individual cells, or electroporation of ES cells, which  
are preferred for mammalian systems, are not suited to  
avian systems. For practice of the present invention  
on avian systems, the method of Bosselman et al.,  
15 described below, is preferred.

Even though the embryo of newly-laid fertile  
bird egg has undergone significant development, it is  
still pluripotent. Injection of a modified avian  
leukosis virus bearing the foreign DNA ("transgene")  
20 into the yolk near the embryo results in infection of  
embryonic cells and integration of the transgene into  
the genome of those cells. The resulting birds  
(generation "G-0") are chimeric, and carry the  
transgene in their germ cells at a useful frequency.  
25 Genetic screening of the G-0 birds followed by  
conventional animal breeding and progeny testing are  
then applied to obtain birds homozygous for the  
transgene. The preferred method for production of  
transgenic birds lacking PrP genes comprises:  
30 (1) inserting the DNA targeting fragment into an  
avian retrovirus-derived vector by  
conventional recombinant DNA techniques,

- 21 -

- (2) injecting the targeting fragment-bearing retrovirus into the yolk of a newly laid fertile egg, near the embryo,
- (3) screening newly hatched chicks (G-0) for integrated proviral/targeting fragment DNA (eg., by a dot-blot procedure),
- (4) mating viremic G-0 male birds selected in step (3) to specific pathogen free females,
- (5) screening chicks (generation "G-1") produced in step (4) for integrated proviral/targeting fragment DNA,
- (6) mating G-1 birds to each other, and
- (7) screening chicks (generation "G-2") produced in step (6) for site-specific integration of the targeting fragment (eg., by PCR techniques or Southern hybridization analysis).

The preceding discussion focusses on the differences between production of transgenic mammals and transgenic birds. It should be apparent that practice of the present invention on avian species requires a suitable cloned PrP gene for construction of the targeting fragment. Such a gene can be obtained by conventional recombinant DNA techniques, including use of published chicken PrP protein partial amino acid sequences to synthesize oligonucleotide probes for screening a avian DNA library. Another method of obtaining an avian PrP gene involves screening an avian DNA library with a fragment of a previously cloned mammalian PrP gene. One of skill in the art will also recognize that since no antibiotic resistance marker is involved in the method described above for production of a transgenic bird, the disrupting sequence inserted into the cloned PrP gene during construction of the

- 22 -

targeting molecule need not be an antibiotic resistance gene.

In view of the above, it should be apparent that the practice of this invention is not limited to a particular animal species, a particular pluripotent cell type for transformation by the foreign DNA, or a particular technique for introducing foreign DNA into the pluripotent cell. One of skill in the art will readily select cell culture and DNA delivery systems appropriate to the animal species.

The mouse is a convenient model system for the present invention. In addition to the obvious economies in feeding and maintenance that accompany the use of a small mammal species, the large litter size and short gestation period are important considerations for rapid progress on the invention. Furthermore, experimental transmission of scrapie to mice and hamsters (Chandler, Lancet 1, pp. 1378-79 (1961); Zlotnik and Rennie, J. Comp. Pathol. 75, pp. 147-57 (1965)) has provided a valuable laboratory model for determining the nature of the infectious agent and studying the disease. While the Examples set forth below recite experiments performed on mice, for the foregoing reasons, the gene transfer technology necessary for the practice of this invention has already been extended to commercially important livestock such as sheep, goats, pigs and cattle (Pursel et al. Science 244, pp. 1281-88).

In order that the invention described herein may be more fully understood, the following examples are set forth. It should be understood that these examples are for illustrative purposes only and are not to be construed as limiting this invention in any manner. Throughout these examples, all molecular cloning reactions were carried out according to methods

- 23 -

in T. Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory (1982) or J. Sambrook et al., Molecular Cloning - A Laboratory Manual, 2nd Ed., Cold Spring Harbor Press (1989), using  
5 commercially available enzymes except where otherwise noted.

### Example 1

#### Construction Of Targeted DNA Molecules For Disrupting Prion Encoding Sequences By Homologous Recombination

10

We constructed targeting vector pRVPrP-3 (Figures 1-5) by replacing codons 4 to 187 of the 254-codon PrP open reading frame (552 bp extending from nucleotide 10 to 562), with a 1.1 kb fragment  
15 containing the HSV TK promoter followed by a neomycin phosphotransferase ("neo") gene. The neo gene confers resistance to neomycin, kanamycin and G418 (Genecitin®). DNA starting materials consisted of the Westaway cosmid (a gift from David Westaway) (described  
20 below), plasmid pBluescript, a commercially available mammalian expression plasmid (see Short et al., Nuc. Acids Res. 16, p. 7583 (1988); product literature from Strategene Cloning Systems) and pMC1neoPA, a commercially available neomycin resistance plasmid (see  
25 Thomas and Capecchi, Cell, 51, pp. 503-12 (1987); product literature from Strategene Cloning Systems).

The Westaway cosmid consists of (BamHI and EcoRI-cleaved) pUC18 (see product literature from GIBCO-BRL, Gaithersburg, MD; Yanisch-Perron et al.,  
30 Gene 33, p. 103 (1985)) with an 8.9 kb BamHI-BamHI mouse genomic insert containing Prn-p exon 3 (which encodes the entire prion protein) and part of the adjacent intron. We subcloned a 4.2 kb BamHI-EcoRI fragment containing exon 3 and the partial intron into  
35 the (BamHI and EcoRI-cleaved multiple cloning site

- 24 -

("MCS") of pBluescript to produce a first intermediate plasmid, pBluescriptPrP2 (Fig. 1). We excised the neo gene and its expression control sequences ("neoPA expression cassette") from pMC1neo with XhoI and SallI and inserted it by blunt-end ligation at the BstEII site (near codon 187) of exon 3, to produce a second intermediate plasmid, pRVPrPneoPA2 (Fig. 2).

The final step in constructing targeting plasmid, pRVPrP3, involved ligation of 3 fragments (Fig. 5). "Fragment 1", the 5.5 kb PstI-ClaI fragment of pBluescriptPrP2, contains the Bluescript vector and PrP intron sequence between the BamHI site and the PstI site (Fig. 3). "Fragment 2", the 1.7 kb XhoI-ClaI fragment of pRVPrPneoPA-2 contains the neoPA expression cassette followed by the remaining PrP coding sequence downstream from the obliterated BstEII, non-coding sequences extending to the EcoRI site, and part of the Bluescript MCS region (Fig. 3). "Fragment 3", required to reconstruct the region between the PstI site in the intron and the XhoI site at the 5' end of the neoPA cassette, was generated by polymerase chain reaction ("PCR"), using linearized pBluescript-PrP2 as the template. The 5' terminal primer, "P5" (SEQ ID NO:1):

(5')GCTTTCTTCA AGTCCTTGCT CCTGCTGTAG(3'),

is complementary to intron sequences upstream of the PstI site. The 3' terminal primer, "PrP-Xho" (SEQ ID NO:2):

(5')TGACTCGAGG GTTCGCCATG ATGACT(3'),

is complementary to the intron-exon boundary, and has an artificial XhoI site (underlined) near its 5' end. We obtained the 0.49 kb "fragment 3" by digesting the reaction product with PstI and XhoI. "Fragment 3"

- 25 -

extends from the PstI site to position +10 (relative to the PrP initiation codon).

We isolated the 4.8 kb ClaI-SacII fragment of pRVPrP-3, for use as a targeting fragment in  
5 transfections (Fig 5). The targeting fragment comprises the neoPA cassette flanked at one end by the mouse intron sequence and part of the PrP 5' non-coding sequence, and at the other end, by the 3' 28% of the PrP coding sequence and the 3' non-coding region of the  
10 PrP gene.

#### Example 2

##### Generation And Characterization OF ES Cells And Mice With Disrupted Prn-p Genes

##### Cell Culture and Electroporation

15 We cultured strain AB-1 murine embryonic stem ("ES") cells (derived from agouti sv129 mice) on irradiated G418-resistant,\* leukemia inhibitory factor ("LIF")-expressing SNL76/7 feeder cells and passaged 1/6 every 2 days in DMEM 20% FCS. Both cell lines were  
20 provided by A. Bradley (McMahon and Bradley, Cell 62, 1073-85, (1990)).

We distributed about  $3 \times 10^7$  trypsinized cells in 1.4 ml PBs into 2 cuvettes and electroporated with about 10  $\mu$ g of purified ClaI-SacII targeting  
25 fragment described in Example 1 (above), in each cuvette. For electroporation, we used standard techniques (see generally, Chu et al., Nuc. Acids. Res. 15, p. 1311 (1987)) and a commercially available apparatus (BioRad Gene Pulser). Our electroporation  
30 parameters were 240 v/500  $\mu$ F.

---

\* G418 (commercially available as Genecitin®, GIBCO BRL, Gaithersburg, MD) is a neomycin-type antibiotic to which ES cells are normally sensitive and to which the neo gene confers resistance.

- 26 -

Identification of ES Cells with the Targeting  
Fragment Integrated by Homologous Recombination

We used a 2-step selection strategy to identify ES clones with the targeting fragment integrated at the proper locus by homologous recombination. Since the targeting fragment contains the neoPA cassette, cells that integrate that fragment into a chromosome, either by random insertion or by homologous recombination, express neomycin resistance. Following electroporation, we plated the cells onto (10) 90 mm feeder plates. After 24 hours we added 0.3 mg G418/ml of medium, as the first selection step. After 10-12 days we picked G418-resistant colonies into individual wells of a 96-well plate, trypsinized them, and resuspended them. We plated aliquots of the cell suspensions onto irradiated feeder cells in 48-well master plates, and pooled the remaining cells of each well in groups of 12. We used PCR techniques (see generally, Sambrook et al., (supra), Chapter 14) to identify G418-resistant colonies with the targeting sequence integrated by homologous recombination. We lysed about 50,000 cells for each PCR analysis. Our PCR techniques were essentially as described by Saiki et al. (Science, 239, pp. 487-91 (1988)). We cycled 35 times for 1 min. at 94° C, and 3 min. at 70° C, with primers "P3" (SEQ ID NO:3):

(5')ATTCGCAGCG CATCGCCTTC TATCGCC(3'),  
which is complementary to the 3' end of the neoPA cassette, and "P4" (SEQ ID NO:4):

(5')CCTGGGAATGAACAAAGGTTTGCTTTCAAC(3'),  
which is complementary to PrP genomic sequences adjacent to the targeting fragment (Fig. 5). These primers give rise to an 850-bp PCR product only when the targeting fragment is integrated into the PrP locus. A positive control ES cell was generated by

- 27 -

transforming D3 ES cells with a construct that contained additional 3' flanking sequences (the 1.3 kb EcoRI-XbaI segment shown in Fig. 1), including the primer binding site for P4, absent from the targeting  
5 vector.

After transformed murine ES cell clone ESAP-37/10 gave positive results in the PCR screening (above), we used Southern hybridization analysis to confirm that clone ESAP-37/10 had one Prn-p allele  
10 disrupted by the targeting fragment. Our probe in the Southern analysis was probe A, a 0.650 kb BstEII-EcoRI fragment mapping to the 3' end of the targeting fragment, which hybridizes to both endogenous and exogenous PrP sequences.

15 Generation of Chimeric Mice from Transformed ES Cells

We injected blastocysts from C57BL/6 (black) mice with ESAP-37/10 cells, and implanted the blastocysts into foster mothers (genotype ICR) essentially as described by Bradley ("Production and  
20 Analysis of Chimaeric Mice", in Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, (E.J. Robertson, ed.) Oxford IRL Press, pp. 113-51, (1987)). About 45% of the resulting offspring were partially, and 35% more than 90% chimeric in agouti coat color.

25 Example 3

Transgenic Mice -- Breeding And Progeny Analysis

Chimeric males were mated at age 7 weeks to C57BL/6J females. Of 22 fertile males, 9 high grade and 3 medium (20-30%) grade transmitted the agouti  
30 marker to their offspring. We determined progeny genotype by PCR analysis of tail DNA (Hogan et al., Manipulating the Mouse Embryo, Cold Spring Harbor Press (1986)). We used primers P10 and P4 in separate

- 28 -

reactions to show the presence of the normal PrP allele (1.1 kb band). Primer P10 (SEQ ID NO:5):

(5')GTACCCATAA TCAGTGGAAC AAGCCCAGC(3')

hybridizes to the PrP sequences that were replaced by  
5 the neoPA cassette in the recombined allele. Samples  
were recycled 35 times for 1 min. at 94° C, 2 min. at  
66° C, 1 min. at 70° C. We confirmed PCR genotype  
results by Southern hybridization analysis. For  
Southern analysis, we blotted and hybridized XbaI-  
10 cleaved DNA with either probe A (see above) or a probe  
encompassing the neoPA sequence, derived from pMC1neoPA  
(Stratagene).

Screening of 147 agouti offspring showed  
about 50% to be heterozygous for the disrupted Prn-p  
15 allele. Southern hybridization analysis confirmed the  
presence of the disrupted gene ("Prn-p<sup>0</sup>"). Only a  
single copy of the targeting sequence had been  
integrated into the mouse genome, as shown by the fact  
that a probe specific for the neo gene hybridized only  
20 a single XbaI fragment of the expected length, 4 kb.  
Because the targeting sequence contained only a single  
XbaI site, each integration event should yield  
additional fragments of 4.8 or 5.4 kb, depending on  
their orientation relative to each other.

25 Mating of Prn-p<sup>0/+</sup> heterozygotes yielded 103  
superficially indistinguishable progeny. PCR analysis  
of the DNA of the 103 progeny revealed that 23% were  
homozygous for the wild type PrP gene, 52% were  
heterozygous, and 25% were homozygous for the disrupted  
30 PrP gene. Southern hybridization analysis confirmed  
the genotype of the homozygous Prn-p<sup>0/0</sup> mice. The  
average life span of these homozygotes has not yet been  
determined, but no spontaneous deaths occurred up to 13  
weeks.

- 29 -

Example 4Analysis Of Brain Tissue Of  
Homozygous Prn-p<sup>0/0</sup> Mice

Northern analysis of Prn-p<sup>0/0</sup> mice revealed no  
5 detectable amount of full-length PrP mRNA. However, as  
expected, we detected a neo-PrP fusion transcript by  
using a neo probe or probe A. Similarly, Western  
analysis of brain extracts from Prn-p<sup>0/0</sup> mice, using  
anti-PrP polyclonal antibodies revealed no detectable  
10 prion protein.

Example 5Gross Anatomy Of  
Homozygous Prn-p<sup>0/0</sup> Mice

We observed no gross abnormalities in the  
15 homozygous Prn-p<sup>0/0</sup> mice. Brain anatomy, as judged by  
microscopic examination of serial sections, appeared  
normal. Some mice showed localized vacuolization in  
the hippocampus, but the incidence was similar in wild  
type, heterozygous Prn-p<sup>0/+</sup> and homozygous Prn-p<sup>0/0</sup>  
20 animals. Thus, the hippocampal vacuolization is  
unrelated to PrP gene disruption.

Example 6Resistance to Scrapie InfectionMice Devoid of Prion Protein

25 We subjected 57 homozygous Prn-p<sup>0/0</sup> mice  
(devoid of prion protein) and 57 Prn-p<sup>+/+</sup> mice (normal  
controls) to scrapie inoculation. We inoculated the  
mice of both groups intracerebrally with a high dose  
(about 10<sup>7</sup> infectious units) of the Chandler strain of  
30 mouse-adapted prions. We sacrificed 4 animals from  
each group after 4 days, and after 2, 8, 12 and 20  
weeks. From each sacrificed animal, we recovered the

- 30 -

brain and spleen for infectivity determination. We also subjected the brain to histological examination.

The normal control mice showed scrapie symptoms at  $158 \pm 11$  days, and they died at  $171 \pm 11$  days. The mice devoid of prion protein appeared healthy 252 days after inoculation, which was 49 days after the last Prn-p<sup>+/+</sup> controls died.

The infectivity time-course experiment revealed that brain extracts from control mice, at 12 weeks after inoculation, gave rise to disease in CD-1 indicator mice after 140 days. In the corresponding tests with brain or spleen extracts from mice devoid of prion protein, no detectable transmission of scrapie occurred.

The above results show that mice devoid of prion protein are completely protected against spongiform encephalopathy. The above results also indicate that mice devoid of prion protein cannot propagate scrapie.

#### 20 Mice With Reduced Levels of Prion Protein

Heterozygous Prn-p<sup>0/+</sup> mice have only one gene encoding prion protein, rather than two. Such heterozygotes produce prion protein, but at a lowered level, due to a gene dosage effect.

To test for scrapie resistance resulting from a lower-than-normal (but non-zero) prion protein level, we inoculated a Prn-p<sup>0/+</sup> heterozygote intracerebrally with about  $10^7$  infectious units of the Chandler strain of mouse-adapted prions. The heterozygous mouse appeared healthy 260 days after inoculation. In a similar scrapie resistance test involving a group of heterozygous Prn-p<sup>0/+</sup> mice, the heterozygous mice appeared healthy at 150 days after inoculation.

- 31 -

The demonstration that Prn-p<sup>0/+</sup> heterozygous mice are much more resistant to scrapie than a wild-type (i.e., Prn-p<sup>+/+</sup>) mice indicates that even a moderate reduction of prion protein synthesis confers  
5 at least partial protection against spongiform encephalopathy.

## Example 7

Gene Complementation Tests

To conclusively demonstrate that the observed  
10 resistance to scrapie infection and transmission was caused by the absence of prion protein, we re-introduced prion genes into our transgenic Prn-p<sup>0/0</sup> mouse strain and tested for restoration of scrapie susceptibility. In this experiment, we used tgHaPrn-p  
15 mice. The tgHaPrn-p strain (produced by Stanley Prusiner et al.) is homozygous for a chromosome bearing 30-50 copies of the Syrian hamster Prn-p gene. The tgHaPrn-p mouse strain is highly susceptible to hamster prions and somewhat less susceptible to mouse prions  
20 than wild type (Prn-p<sup>+/+</sup>) mice. We mated Prn-p<sup>0/0</sup> mice with tgHaPrn-p mice and identified Prn-p<sup>0/+</sup>/HaPrn-p<sup>0/+</sup> progeny. We backcrossed those progeny with Prn-p<sup>0/0</sup> mice and identified Prn-p<sup>0/0</sup>/HaPrn-p<sup>0/+</sup> individuals. We inoculated (as described above) groups of 9-11 Prn-  
25 p<sup>0/0</sup>/HaPrn-p<sup>0/+</sup> mice with Chandler strain mouse scrapie prions or Sc237 strain hamster prions. The mice inoculated with hamster prion strain Sc237 showed neurological symptoms after  $56 \pm 3$  days, and died after  $59 \pm 5$  days. As of 140 days after inoculation, the  
30 mice that received the mouse prions were without disease symptoms.

- 32 -

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

- (i) APPLICANT: Weissmann, Charles  
Bueler, Hansruedi  
Aguet, Michel  
Fischer, Marek
- (ii) TITLE OF INVENTION: TRANSGENIC ANIMALS LACKING PRION  
PROTEINS
- (iii) NUMBER OF SEQUENCES: 5
- (iv) CORRESPONDENCE ADDRESS:
  - (A) ADDRESSEE: c/o FISH & NEAVE
  - (B) STREET: 875 Third Avenue
  - (C) CITY: New York
  - (D) STATE: New York
  - (E) COUNTRY: United States of America
  - (F) ZIP: 10022
- (v) COMPUTER READABLE FORM:
  - (A) MEDIUM TYPE: Floppy disk
  - (B) COMPUTER: IBM PC compatible
  - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
  - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
  - (A) APPLICATION NUMBER:
  - (B) FILING DATE: 14-NOV-1991
  - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
  - (A) NAME: Haley Jr., James F.
  - (B) REGISTRATION NUMBER: 27,794
- (ix) TELECOMMUNICATION INFORMATION:
  - (A) TELEPHONE: (212) 715-0600
  - (B) TELEFAX: (212) 715-0674
  - (C) TELEX: 14-8367

## (2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 30 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GCTTTCTTCA AGTCCTTGCT CCTGCTGTAG

- 33 -

## (2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 26 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

TGACTCGAGG GTTCGCCATG ATGACT 26

## (2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 27 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

ATTGCGAGCG CATCGCCCTTC TATCGCC 27

## (2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 30 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

CCTGGGAATG AACAAAGGTT TGCTTTCAAC 30

## (2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 29 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

GTACCCATAA TCAGTGGAAC AAGCCCAGC 29

- 34 -

We claim:

1. A transgenic mammal or bird having no functional prion protein.
2. A transgenic mammal or bird one or more of whose prion protein-encoding genes in its germ or somatic cells has been disrupted by a targeting molecule.
3. A DNA targeting molecule capable of specifically disrupting prion protein gene sequences in mammalian or avian cells.
4. A mammalian or avian cell transformed with a DNA targeting molecule according to claim 3, wherein the DNA targeting molecule has disrupted one or more of the cell's prion protein-encoding genes.
5. The mammalian or avian cell according to claim 4, wherein the DNA targeting molecule is plasmid pRVPrP3 or a fragment thereof.
6. The mammalian or avian cell according to claim 5, wherein the recombinant DNA molecule is the 4.8 kb ClaI-SacII fragment of plasmid pRVPrP3.
7. A transgenic mammal or bird derived from cells according to any one of claims 4, 5 or 6.
8. A transgenic mammal according to any one of claims 1, 2 or 7 belonging to a genus selected from the group consisting of: (a) Mus, (b) Rattus, (c) Mesocricetus, (d) Oryctolagus, (e) Sus, (f) Ovis and (g) Bos.

- 35 -

9. A transgenic mouse according to claim 8.

10. A DNA molecule selected from the group consisting of plasmid pRVPrP3, and the 4.8 kb ClaI-SacII fragment of that plasmid.

11. A method of producing transgenic mammals or birds having no functional prion protein, comprising the steps of:

- (a) constructing a targeting molecule by inserting a disrupting nucleotide sequence into a cloned prion gene so that
  - (i) the disrupting insert is flanked by sequences specific to the prion protein gene locus, and
  - (ii) a functional prion protein can no longer be expressed from the disrupted gene;
- (b) introducing the targeting molecule into a mammalian or avian cell;
- (c) using a transformed cell having a prion gene disrupted by homologous recombination with the targeting molecule or a fragment thereof to produce a transgenic animal characterized by cells with a disrupted prion gene;
- (d) breeding transgenic animals carrying a disrupted prion gene to produce descendants homozygous for disrupted prion genes.

12. A method of producing transgenic mammals or birds according to claim 11, wherein the recombinant DNA molecule that disrupts the prion protein gene is plasmid pRVPrP3 or a fragment thereof.

13. A recombinant DNA molecule comprising a sequence of at least five nucleotides from a prion gene

- 36 -

or analog thereof, said sequence being operably linked in the antisense orientation to a eukaryotic expression control sequence.

14. A mammalian or avian cell transformed with a recombinant DNA molecule according to claim 13.

15. A transgenic mammal or bird having germ or somatic cells transformed with a recombinant DNA molecule according to claim 13.

16. A method of producing transgenic mammals or birds having germ or somatic cells with a reduced amount of prion protein, comprising the steps of:

(a) constructing a recombinant antisense DNA molecule comprising a sequence of at least five nucleotides from a prion gene or analog thereof, said sequence being operably linked in the antisense orientation to a eukaryotic expression control sequence;

(b) introducing the recombinant antisense DNA molecule into a mammalian or avian cell; and

(c) using the cell transformed with a prion antisense DNA molecule to produce a transgenic animal.

17. A method for treating spongiform encephalopathy, comprising administration of a prion antisense oligonucleotide.

18. An RNA molecule comprising a ribozyme sequence fused to a prion antisense sequence.


19. A recombinant DNA molecule encoding an RNA molecule according to claim 18.

- 37 -

20. A method for treating spongiform encephalopathy, comprising administration of a prion antisense oligonucleotide fused to a ribozyme sequence.

1 / 5

FIG. 1



2 / 5

FIG. 2






FIG. 3






5' PRIMER SEQUENCE: (5')GCTTCTCAAGTCCTTGCTCCTGCTGTAG (3')

3' PRIMER SEQUENCE: (5')TGACICGAGGGTCGCCATGATGACT (3')

FIG. 4

5 / 5



SUBSTITUTE SHEET

## INTERNATIONAL SEARCH REPORT

PCT/EP 92/02631

International Application No

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (If several classification symbols apply, indicate all) <sup>6</sup>		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int.Cl. 5 C12N15/00; C12N5/10;	C12N15/11; C12N15/12	A61K48/00; A01K67/027
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched <sup>7</sup>		
Classification System	Classification Symbols	
Int.Cl. 5	C12N ; A61K ; C07K	
Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched <sup>8</sup>		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup></b>		
Category <sup>a</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
P,X	NATURE. vol. 356, no. 6370, 16 April 1992, LONDON GB pages 577 - 582 BUELER, H. ET AL. 'Normal development and behaviour of mice lacking the neuronal cell surface PrP protein' see the whole document ---	1-17
Y	CELL. vol. 46, no. 3, 1 August 1986, CAMBRIDGE, NA US pages 417 - 428 BASLER, K. ET AL. 'Scrapie and cellular PrP isoforms are encoded by the same chromosomal gene' cited in the application see the whole document --- -/-	1-20
<p><sup>a</sup> Special categories of cited documents :<sup>10</sup></p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to underscore the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"A" document member of the same patent family</p>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search		Date of Mailing of this International Search Report
16 MARCH 1993		24.03.93
International Searching Authority		Signature of Authorized Officer
EUROPEAN PATENT OFFICE		CHAMBONNET F.J.

REL DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		Relevant to Claim No.
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	
Y	<p>PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA. vol. 83, no. 17, September 1986, WASHINGTON US pages 6377 - 6381 ROBAKIS, N.K. ET AL. 'Isolation of a cDNA clone encoding the leader peptide of prion protein and expression of the homologous gene in various tissues' see the whole document</p> <p>---</p>	1-20
Y	<p>NATURE. vol. 352, no. 6337, 22 August 1991, LONDON GB pages 679 - 683 WEISSMANN C. 'A "unified theory" of prion propagation' see the whole document</p> <p>---</p>	1-20
Y	<p>WO,A,9 101 140 (CELL GENESYS, INC.) 7 February 1991 see the whole document</p> <p>---</p>	1-15
Y	<p>WO,A,8 605 516 (DUKE UNIVERSITY) 25 September 1986 see the whole document</p> <p>---</p>	1-16
P,Y	<p>WO,A,9 117 174 (NEUROGENETIC CORPORATION) 14 November 1991 see claims 32-42, 60-64, 77, 79, 82</p> <p>---</p>	16
Y	<p>PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA. vol. 88, no. 10, May 1991, WASHINGTON US pages 4313 - 4317 HAN, L. ET AL. 'Inhibition of Moloney murine leukemia virus-induced leukemia in transgenic mice expressing antisense RNA complementary complementary to the retroviral packaging sequences' see the whole document</p> <p>---</p>	16
Y	<p>JOURNAL OF THE NATIONAL CANCER INSTITUTE vol. 81, no. 20, 18 October 1989, pages 1539 - 1545 ROTHENBERG, M. ET AL. 'Oligonucleotides as anti-sense inhibitors of gene expression : therapeutic implications' see page 1543, column 2, line 17 - page 1545, column 2, line 14</p> <p>---</p>	17-20

-/-

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
P,Y	TRENDS IN BIOTECHNOLOGY vol. 10, no. 5, May 1992, pages 152 - 158 AGRAWAL, S. 'Antisense oligonucleotides as antiviral agents' see the whole document -----	17-20

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP 92/ 02631

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark:  
Although claims 17 and 20 are directed to a method of treatment of the human/animal body the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO.**

EP 9202631  
SA 67042

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

16/03/93

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9101140	07-02-91	AU-A- 6150590	22-02-91
		EP-A- 0437576	24-07-91
		JP-T- 4501510	19-03-92
-----			
WO-A-8605516	25-09-86	EP-A- 0215907	01-04-87
		EP-A- 0477994	01-04-92
		JP-T- 62502863	19-11-87
-----			
WO-A-9117174	14-11-91	US-A- 5155218	13-10-92
		AU-A- 7879891	27-11-91
		EP-A- 0530265	10-03-93
-----			

EPO FORM P0079

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82